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Abstract
Advanced congestive heart failure (CHF) and chronic kidney disease (CKD) are characterized by increased angiotensin II (Ang
II) levels and are often accompanied by significant skeletal muscle wasting that negatively impacts mortality and morbidity.
Both CHF and CKD patients have respiratory muscle dysfunction, however the potential effects of Ang II on respiratory
muscles are unknown. We investigated the effects of Ang II on diaphragm muscle in FVB mice. Ang II induced significant
diaphragm muscle wasting (18.761.6% decrease in weight at one week) and reduction in fiber cross-sectional area.
Expression of the E3 ubiquitin ligases atrogin-1 and muscle ring finger-1 (MuRF-1) and of the pro-apoptotic factor BAX was
increased after 24 h of Ang II infusion (4.460.3 fold, 3.160.5 fold and 1.660.2 fold, respectively, compared to sham infused
control) suggesting increased muscle protein degradation and apoptosis. In Ang II infused animals, there was significant
regeneration of injured diaphragm muscles at 7 days as indicated by an increase in the number of myofibers with
centralized nuclei and high expression of embryonic myosin heavy chain (E-MyHC, 11.263.3 fold increase) and of the
satellite cell marker M-cadherin (59.2622.2% increase). Furthermore, there was an increase in expression of insulin-like
growth factor-1 (IGF-1, 1.860.3 fold increase) in Ang II infused diaphragm, suggesting the involvement of IGF-1 in
diaphragm muscle regeneration. Bone-marrow transplantation experiments indicated that although there was recruitment
of bone-marrow derived cells to the injured diaphragm in Ang II infused mice (267.0674.6% increase), those cells did not
express markers of muscle stem cells or regenerating myofibers. In conclusion, Ang II causes marked diaphragm muscle
wasting, which may be important for the pathophysiology of respiratory muscle dysfunction and cachexia in conditions
such as CHF and CKD.
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Introduction
Muscle wasting is associated with ageing and several chronic
diseases including congestive heart failure (CHF) [1,2,3,4], chronic
kidney disease (CKD) [5], chronic obstructive pulmonary disease
[6] and cancer [7]. Loss of lean body mass increases the mortality
and morbidity of chronic disease states, e.g., it is a major predictor
of poor outcome in CHF [8]. Muscle atrophy in chronic diseases is
not restricted to limb muscles; it may also affect respiratory
muscles which work continuously during life and have a higher
ability to overcome fatigue compared to limb muscles, perhaps due
to higher blood flow, capillary density, mitochondrial content,
antioxidant capacity and oxygen consumption [9]. Thus respira-
tory muscle function and in particular function of the diaphragm is
compromised in patients with chronic obstructive pulmonary
disease [6,9], CHF and CKD [2,10].
The etiology of muscle wasting in chronic disease states is
certainly multifactorial [11], and involves changes in physical
activity, appetite and nutrient intake and increases in inflamma-
tory mediators and cytokines such as TNF-a and IL-6 [12,13]. It is
of note that patients with CHF and CKD have stimulation of the
renin-angiotensin system and often have high levels of circulating
angiotensin II, even in the presence of angiotensin-converting
enzyme inhibitor therapy [14,15]. Studies from our laboratory
have previously shown that Ang II infusion in rodents induced
catabolic hind limb muscle wasting, secondary to multiple
mechanisms including reduced insulin-like growth factor-1 (IGF-
1) signaling, stimulation of the ubiquitin-proteasome pathway of
protein degradation [16,17] and increased skeletal muscle
apoptosis. While these findings have suggested that Ang II could
contribute to muscle wasting in chronic disease states the potential
effect of Ang II on respiratory muscles remains unknown. This
study was designed to investigate whether Ang II induced
diaphragmatic muscle wasting and to obtain initial insights into
mechanisms involved.
Results
Ang II induced diaphragmatic muscle wasting
To determine the potential effect of Ang II on diaphragmatic
skeletal muscle, 9 week old FVB mice were subcutaneously infused
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Fig. 1A, Ang II induced significant diaphragmatic muscle wasting
after 7 days, whereas Ang II had no significant effect at 24 h.
Induction of diaphragmatic muscle atrophy was confirmed by a
reduction in cross sectional area (CSA) of diaphragm myofibers
(Fig. 1B, 26% leftward shift of myofiber area distribution curve).
After 24 h of Ang II infusion, mRNA expression levels of the
ubiquitin ligases atrogin-1 (Fig. 1C) and muscle ring finger-1
(MuRF-1) (Fig. 1D) were increased 4.660.3 and 3.160.5 fold,
respectively, compared to sham infused mice, whereas there was
no difference on day 7. Expression of the pro-apoptotic marker
BAX was also elevated (1.660.2 fold) in response to Ang II
infusion on day 1 (Fig. 1E).
Regeneration of diaphragmatic skeletal muscle in
response to Ang II-induced injury
Hematoxylin and Eosin (H&E) stained sections showed
centralized myonuclei at 7 days in Ang II infused animals
(Fig. 2A), consistent with skeletal muscle regeneration. Quantita-
tive PCR results indicated that expression of embryonic myosin
heavy chain (E-MyHC) was increased 11.263.7 fold in diaphragm
from Ang II infused mice compared to sham infused controls at
one week (Fig. 2B). Immunohistochemical staining confirmed the
increase of E-MyHC in the diaphragm of Ang II infused mice on
day 7 (Fig. 2C). These E-MyHC positive myofibers were
characterized by centralized nuclei (Fig. 2C, 3
rd row) and
longitudinal sections (4
th row) indicated the location of satellite
cells in the newly formed myofibers (white arrows). Insulin-like
growth factor-1 (IGF-1) plays a permissive role in satellite cell
activation and regeneration of skeletal muscle [18,19,20,21].
Expression of IGF-1 in the diaphragm was significantly elevated
after one week of Ang II infusion (Fig. 2D). The expression of IGF-
1 receptor (IGF-1R) was significantly elevated at day one of Ang II
infusion but then decreased at day 7 (Fig. 2E). Western blotting of
diaphragm lysates demonstrated a 59.2622.2% increase in
expression of the activated satellite cell marker M-cadherin
(N=4, p=0.08) after 7 days of Ang II infusion, consistent with
diaphragm muscle regeneration (Fig. 2F).
Recruitment of bone marrow derived cells
Skeletal muscle injury induces inflammatory cell recruitment to
the injured site to remove necrotic debris and to initiate the repair
process [22], which involves activation, proliferation and differ-
entiation of myogenic progenitor cells to repair or replace
damaged muscle fibers. It has been shown that bone-marrow
derived cells can be incorporated into injured skeletal muscle to
form myotubes [23], although there is much evidence that muscle
regeneration after injury involves predominantly local myogenic
progenitor cells, called satellite cells [24,25,26]. To determine if
Ang II-induced skeletal muscle injury and regeneration was
associated with the recruitment of bone marrow derived muscle
stem cells lethally irradiated mice were injected with bone marrow
cells from GFP transgenic mice and infused with Ang II or saline
three weeks after bone marrow transplantation. Our results
indicated that bone marrow-derived GFP positive cells were
significantly recruited into diaphragm of Ang II infused mice
(Fig. 3A). However, none of the recruited cells were positive for the








+ [27,28] (Fig 3A).
Furthermore, none of these cells expressed the satellite cell
markers MyoD or M-cadherin (Fig. 3B, C) or a marker of
regenerating myofibers E-MyHC (Fig. 3D).
Discussion
Ang II infusion for 7 days markedly reduced muscle weight and
CSA of diaphragm myofibers (Fig. 1A, B), indicating that Ang II
induced respiratory muscle atrophy. In previous studies we have
shown that Ang II produced hind limb muscle wasting in rodents
[16,17,29,30,31]. These studies demonstrated that the catabolic
effect of Ang II was the result of alterations in several signaling
pathways, namely reduced IGF-1/Akt signaling, increased cas-
pase-3 activity, an increase in E3 ubiquitin ligase atrogin-1 and
muscle ring finger-1 (MuRF-1) expression leading to increased
activity of the ubiquitin-proteasome proteolytic pathway [32] and
increased apoptosis of skeletal muscle. Consistent with our
previous report on hind limb muscles, mRNA expression levels
of atrogin-1, MuRF-1 and of the pro-apoptotic marker BAX were
significantly elevated after 24 h of Ang II infusion (Fig. 1C, D and
E), strongly suggesting that Ang II induced atrophy of the
diaphragm also involved increased apoptosis and increased
activation of the ubiquitin-proteasome pathway of protein
degradation. We have previously shown a marked increase of
caspase-3 activity and of ubiquitinated proteins in the skeletal
muscle of Ang II infused mice [16]. However, contrary to what we
have observed in hind-limb muscle (where we have detected very
few regenerating myofibers after 7 days of Ang II infusion, data
not shown), the diaphragm of Ang II infused animals showed
Figure 1. Diaphragm Muscle Wasting. (A) Diaphragm weight of
sham at day 1 (Sham-D1), Ang II at day 1 (Ang II-D1), sham at day 7
(Sham-D7) and Ang II at day 7 (Ang II-D7). N=8, Mean6SEM,
###P,0.001. (B) Cross sectional area of diaphragm at day 7 (Sham,
blue; Ang II, red). (C–E) Quantitative RT-PCR of Atrogin-1 (C), MuRF-1 (D)
and BAX (E).
doi:10.1371/journal.pone.0030276.g001
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of myofibers with centralized nuclei and increased expression of E-
MyHC.
Skeletal muscle injury is normally accompanied by muscle
regeneration, in order to repair or replace damaged muscle fibers.
For instance, in Duchenne muscular dystrophy there is ongoing
regeneration in the setting of muscle degeneration and atrophy,
although this regeneration is insufficient to match the pace of
degeneration [33]. Muscle regeneration is characterized by
recruitment of inflammatory cells and bone marrow-derived
progenitor cells, activation and proliferation of muscle stem cells
called satellite cells, differentiation of myoblasts and subsequent
fusion to form immature multinucleated myofibers with central-
ized nuclei, often expressing E-MyHC [34,35]. Our data clearly
indicated evidence of regeneration in diaphragm of Ang II infused
animals, namely centrally located nuclei (Fig. 2A), increased
expression of E-MyHC (Fig. 2B and C) and a strong trend to
increased expression of M-cadherin, a marker of activated satellite
cells [36,37] (Fig. 2F). IGF-1, acting via the IGF-1R, is an
important regulator of skeletal muscle growth and regeneration
Figure 2. Regeneration of Diaphragm Muscles. (A) Representitive hematoxylen and Eosin staining sections at days 1 and 7 for sham and for
Ang II. White arrows show centralized nuclei. (B) Quantitative RT-PCR of embryonic MyHC (E-MyHC). (C) Immunostaining of E-MyHC (green) and
Laminin (magenta). Nuclei were stained with DAPI (blue). First row shows no expression of E-MyHC in the Sham infused mice at day 7(206
magnification). Diaphragm of Ang II infused mice (second row, 206magnification) shows high expression of E-MyHC (green). Higher magnification
(1006) of cross sections (third row) clearly shows the centralized nucleus in the newly formed myofiber. Fourth row represented the longitudinal
section of a newly formed myofiber showing the location of satellite cells (whit arrows). (D, E) Quantitative RT-PCR of IGF-1 (D) and IGF-1R (E). (F)
Immunoblot analysis showed a slight increase of M-cadherin in diaphragm of Ang II infused mice. N=4, Mean6SEM, p=0.08.
doi:10.1371/journal.pone.0030276.g002
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elevated in the diaphragm after one week of Ang II infusion
(Fig. 2D), whereas we have previously shown that IGF-1
expression is reduced by Ang II in hind-limb muscle [16,17].
Furthermore, Ang II increased IGF-1R expression in diaphragm
at 1 day (Fig. 2E), consistent with the known effect of Ang II to
transcriptionally regulate IGF-1R expression in vascular smooth
muscle [40,41]. Of note, at 7 days we observed that IGF-1R
mRNA expression in the diaphragm was reduced in Ang II infused
animals, consistent with the known ability of IGF-1 to downreg-
ulate expression of its receptor in other tissues [42]. Taken
together our findings suggest that IGF-1 may play a role in
regenerative processes in the diaphragm in the setting of Ang II
induced injury.
To determine whether muscle regeneration in the setting of Ang
II-induced wasting involved recruitment of bone marrow derived
cells, we transplanted bone marrow cells from GFP-transgenic
mice into age matched irradiated recipient mice, followed by Ang
II infusion. Our results indicated that GFP positive cells were
significantly recruited into Ang II injured diaphragm (Fig. 3A).
These findings are in agreement with the studies of LaBarge and
Blau [43], Camargo et al. [44], Musaro ` et al. [45] and Sherwood
Figure 3. Recruitment of bone marrow derived cells. (A) Fluorescence activated cell sorter (FACS) analysis data at day 7 (Sham and Ang II
infused mice) of recruited bone marrow derived cells (GFP
+), and skeletal muscle stem cells (SMSC). N=7, Mean6SEM, **P,0.01. (B–D) Bone marrow
derived GFP positive cells recruited to diaphragm were costained with the satellite cell markers MyoD (B) and M-cadherin (C), and a marker of
regenerating myofibers, E-MyHC (D).
doi:10.1371/journal.pone.0030276.g003
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recruited into injured muscles. However the contribution of bone
marrow derived cells to myogenesis and regeneration is likely not
direct since these cells have minimal capacity to differentiate to
myotubes [27,46]. Under our experimental conditions, none of the









+ were used by Sherwood et al. [27], to
identify myogenic projenitor cells and in our analysis CXCR4
+
was omitted to include GFP. Furthermore, we did not observe
GFP
+ myotubes in our Ang II infused mice, and none of the GFP
positive cells expressed the satellite cell markers MyoD or M-
cadherin or the marker of regenerating myofibers, E-MyHC
(Fig. 3B–D).
Our finding that Ang II causes marked diaphragmatic muscle
atrophy has major clinical implications. Conditions such as CHF
and CKD are often characterized by increased circulating Ang II
levels and the dose of Ang II used in our study produces a 2.8 fold
increase in plasma Ang II [47], consistent with the increase found
in patients with CHF and CKD [14,15,48,49]. Both these
conditions are associated with significant respiratory muscle
dysfunction [2,10] and mechanisms are poorly understood,
although in CHF an increase in oxidant stress and in TNF-a
may play a role [50]. Patients with chronic obstructive pulmonary
disease also have respiratory muscle dysfunction which, in addition
to mechanical causes, has been linked to an increase in atrogin-1
and activated caspase-3 expression and to increased activity of the
ubiquitin-proteasome pathway[6,51]. While there is little infor-
mation on activity of the renin-angiotensin system in patients with
chronic obstructive pulmonary disease [52,53] one could speculate
that Ang II contributes to these changes. Furthermore, McClung
et al. [54] reported that active caspase-3 protein expression was
upregulated in diaphragm muscle during mechanical ventilation-
induced atrophy, and we have previously demonstrated that Ang
II induces caspase-3 activation in skeletal muscle [16].
In summary, our data indicate that Ang II infusion in FVB mice
causes marked diaphragm muscle atrophy. Expression of the E3
ligases atrogin-1 and MuRF-1 and of the pro-apoptotic factor
BAX is increased by Ang II, consistent with increased proteolysis
and apoptosis. In addition there is evidence of regenerating
myofibers in the atrophied diaphragm and evidence of recruitment
of bone-marrow derived cells, although these cells do not express
muscle stem cell markers. Since the diaphragm plays a critical role
in respiration, our findings may be important for understanding
mechanisms of respiratory muscle dysfunction in chronic diseases




All the animal experiments were approved by the Institutional
Animal Care and Use Committee at Tulane University. Male
FVB mice (9 weeks) were obtained from Charles River and were
housed at the Tulane University animal care facilities under
conventional conditions with constant temperature and humidity
and fed a standard diet. FVB mice were subcutaneously infused
with Ang II (1 mg/kg/min) or sham infused using ALZET osmotic
minipumps. After one day and one week animals were sacrificed
using ketamine/xylazine and diaphragms were harvested.
Histology and Immunostaining
Diaphragm was fixed in 10% zinc formalin and paraffin-
embedded. Paraffin sections were processed for Hematoxylin and
Eosin stains to evaluate centrally located myonuclei. The cross-
sectional area (CSA) of diaphragm muscle fibers was calculated by
determination of the circumference of ,40 adjacent cells from
every muscle section examined (n=10 sections/5 mice). The
image was analyzed using Image Pro Plus (Media Cybernetics).
For immunohistochemical staining, sections were fixed with 4%
paraformaldehyde and permeabilized with 0.2% Triton X-100.
After blocking, sections were incubated with primary antibodies
overnight at 4uC. Antibodies used in this study are E-MyHC
(1:100; Developmental Studies Hybridoma bank), Laminin (1:500;
R&D Biosystems), MyoD (1:50; DAKO) and M-cadherin (1:100;
BD Pharmingen). Alexa Fluor 488 or 594-conjugated secondary
antibodies (1:500: Invitrogen) were used for detection. Sections
were analyzed under Olympus 1X81 Fluorescence Microscopy or
Leica Confocal Laser Scanning Microscopy.
Quantitative real-time RT-PCR
Diaphragm muscles were homogenized in Tripure isolation
reagent (Roche), and total RNA was isolated with RNeasy Mini
Kit (Qiagen). cDNA synthesis was performed using the RT
2 first-
strand kit (SABiosciences). Quantitative real-time PCR was
performed using a 40-cycle two-step PCR protocol in the iCycler
IQ real-time detection system (Bio-Rad). Hprt1 gene expression
was used as an internal control. PCR primers used in this study
were obtained from SABiosciences.
Immunoblotting
The tissue lysate (25 mg protein) were subjected to sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
and transferred to a nitrocellulose membrane (Amersham
Pharmacia). The membrane was blocked and incubated with an
antibody against M-cadherin (Abcam) overnight at 4uC. The
membrane was then incubated with the horseradish peroxidase-
conjugated anti-rabbi IgG (Amersham Pharmacia) at a 1: 2000
dilution for 1 h at room temperature. The membrane was then
processed using enhanced chemiluminescence (ECL) western blot
detection reagent (Amersham Pharmacia).
Bone marrow transplantation
Recipient FVB mice (6 weeks) received lethal gamma
irradiation (900 rad). After 4–6 hours, recipient mice received
9610
6 GFP
+ bone marrow cells isolated from the femur and tibia
of age matched enhanced green fluorescent protein (EGFP)
transgenic mice strain that expresses EGFP driven by chicken
beta-actin promoter and CMV immediate early enhancer
(FVB.Cg-Tg(ACTB-EGFP)B5Nagy/J, Jackson Laboratory). After
three weeks recipient mice were infused with Ang II or sham
infused for an additional week. Mice were then euthanized and
perfused with normoosmotic saline. The efficiency of bone
marrow transplantation was 88%, which was tested by quantitat-
ing GFP
+ cells in femur of recipient mice. Diaphragm muscles
were dissected and mononucleated cells were isolated for FACS
analysis as described in the following section.
FACS analysis
Diaphragm muscles were dissected and digested with 100 U/ml
of collagenase type II (Worthington Biomedical Corporation) for
45 min and then 1.25 mg/ml of pronase (Roche) for 45 min at
37uC. Mononucleated diaphragm cells were filtrated with cell
strainer (70 mm) (BD Falcon) and then incubated with primary
antibodies (CD45, CD31, Sca-1, and CD11b, PE; CD34, APC;
Integrin-b1, PE-Cy7. BD pharmingen) for 20 min at room
temperature in the dark. Negative controls of diaphragm cells
Angiotensin II and Respiratory Muscle Atrophy
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samples were washed three times by PBS pH 7.4. Flow cytometry
analysis was performed by FACSVantage (Beckman Coulter).
Statistical analysis
All data were expressed as mean 6 SEM and analyzed using
Student’s t-test (Sham D1 vs Ang II D1 and Sham D7 vs Ang II
D7). A p-value of ,0.05 was considered significant.
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